1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Verde Science, Inc.

Verde Science, Inc.

VRCI
Verde Science, Inc.US flagOther OTC
0.00
USD
- -
- -
477.00Market Cap
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
2014 Y
TTM
Revenue per Share
- -
- -
20.19
81.46
60.1
- -
- -
- -
- -
Basic EPS, GAAP
-108.11
-20.2
-329.7
-274.2
-21.32
-14.43
-2.22
-6.12
-0.03
Free Cash Flow per Basic Share
-95.79
-16.38
-138.83
-176.69
-19.1
-0.18
-1.25
-1.18
-0.01
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-93.94
-113
-442.7
-654.84
-522.01
0.69
-12.23
-16.44
-0.35
Tangible Book Value per Share
4.58
-16
-343.38
-137.11
-99.84
-1.62
-1.41
-1.86
-0.05
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
22
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
-1,621.55
-211.87
-121.95
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
-1
-1
- -
-2
-1
-3
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
-1,633.08
-336.63
-35.48
- -
- -
- -
- -
Working Capital
- -
- -
-1
- -
- -
- -
-1
-1
-1
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
-1
- -
- -
- -
-1
-1
-1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'15
Jun'15
Sep'15
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
24
24
Market Capitalization
5
3
1

Working Capital

FRC

•

in mil. unless spec.
Mar'15
Jun'15
Sep'15
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
19.42%
56.54%
Free Cash Flow
- -
315.89%
11.66%
Net Income, GAAP
- -
692.36%
227.32%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
0.04
-0.97
-0.74
- -
-2.22
2014
-2.48
-3.1
-0.81
- -
-6.12
2015
- -
-0.02
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -
2015
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Harpreet Singh Sangha
Full Time Employees
1
Sector
Healthcare
Industry
Biotechnology
Address
400 South Zang Boulevard Dallas TX United States of America 75208
IPO Date
Feb 10, 2009
CIK
0001390778
Website
verdescienceinc.com
Similar Companies
Oncoinvent ASA (ONCIN.OL)
Telix Pharmaceuticals Limited (TLPPF)
Addex Therapeutics Ltd (ADDXF)
Kyverna Therapeutics, Inc. (KYTX)
Mesoblast Limited (MESO)
Regeneron Pharmaceuticals, Inc. (REGN)
Business
Verde Science, Inc. Verde Science, Inc. (VRCI) is a pharmaceutical research and development company focused on developing a portfolio of cannabinoid-based prescription medicines for various medical conditions; its core offerings include medical marijuana products and related medical science consulting services. The company targets patients and clients in the burgeoning medicinal marijuana industry, providing technical and financial resources to support manufacturing, research, and development efforts in this sector. Founded in 2007 and headquartered in Dallas, Texas, Verde Science, Inc. formerly operated as Rango Energy, Inc., undergoing a name change and ticker symbol update to VRCI in May 2014 to reflect its strategic pivot to pharmaceutical innovation. No major acquisitions, partnerships, funding rounds, new product launches, or significant operational changes have been reported for the company in the last 1-2 years, with the most recent financial disclosures dating back to 2015 showing no revenue generation and ongoing net losses. Verde Science, Inc. maintains a minimal operational footprint with approximately one employee and continues to emphasize cannabinoid therapeutics amid a challenging financial profile, including a microcap market valuation under $25,000.

Company News

APIChat